We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Proteomics International Signs Agreement with inVentiv Health Clinical
News

Proteomics International Signs Agreement with inVentiv Health Clinical

Proteomics International Signs Agreement with inVentiv Health Clinical
News

Proteomics International Signs Agreement with inVentiv Health Clinical

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Proteomics International Signs Agreement with inVentiv Health Clinical"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Proteomics International has signed a collaborative agreement with inVentiv Health Clinical, a leading
provider of global clinical research and bioanalytical services.

Biosimilar and biologic development begins with extensive structural and functional characterization. Proteomics International provides structural characterization and QC testing of proposed and referenced products with an advanced suite of scientific instrumentation. These services complement inVentiv Health’s array of bioanalytical capabilities from clinical development through commercialization in support of biosimilar development.

The Proteomics International agreement with inVentiv Clinical offers developers the ability to seamlessly transition from characterization to clinical trials thereby streamlining the process and providing a competitive advantage in the race to market.

“We welcome the partnership with inVentiv as it represents a significant opportunity for us in furthering expansion into bio-generic markets,” said Dr. Richard Lipscombe, Managing Director of Proteomics International.

Dr. Lipscombe continued, “This collaboration will position both companies to better assist biosimilar and biologics developers in this emerging field and ever-changing regulatory environment.”

“The strengths of Proteomic International to demonstrate biosimilarity combined with inVentiv biologic clinical, commercial and consulting expertise is a winning solution for clients,” said Dr. George Scott, Vice President, Bioanalytical Services for inVentiv Clinical. “Together we offer the full breadth and scope of an integrated roadmap of biosimilar development services to help navigate the complex regulatory and development landscape from early strategic planning, clinical trial conduct, and registration to commercialization.”

Advertisement